Up to $22 million will help test whether one oral drug can preserve independence, resilience and function as we age.
What if aging care started before something broke? What if medicine didn’t wait for memory lapses, mobility loss or chronic disease before stepping in? What if the goal wasn’t to manage decline, but to delay (or even avoid) it altogether?
That question sits at the heart of a new federal award to New Jersey-based biopharma company Linnaeus Therapeutics, which has, as we reported yesterday, secured up to $22 million from ARPA-H to advance its lead drug candidate, LNS8801, for healthspan preservation [1]. The funding comes through ARPA-H’s PROSPR program (short for PROactive Solutions for Prolonging Resilience), a name that reflects a growing shift in how aging is being approached at the highest levels of biomedical research.
Rather than targeting a single disease, the program asks a more foundational question: Can we preserve the physical and cognitive abilities that enable people to remain independent as they age?
Longevity science has long argued that adding years to life without preserving quality is a hollow victory. ARPA-H’s backing of Linnaeus signals that this idea is now moving from philosophy to policy.
At the center of the effort is “Intrinsic Capacity,” a term used to describe the combined physical and mental abilities that underpin resilience later in life. Think of it less as a single organ or metric, and more as the body’s operating system. When it runs well, people adapt, recover and stay engaged. When it degrades, decline accelerates across multiple systems at once.
“This award supports studies that directly assess whether LNS8801 can preserve Intrinsic Capacity and improve healthspan,” says Dr Christopher Natale, cofounder and chief scientific officer of Linnaeus. His team’s interest was sparked by a persistent pattern in real-world data. Across many diseases of aging, women tend to experience better outcomes than men, at least until later in life.
Rather than relying on hormone therapy, Linnaeus focused on a specific estrogen-related pathway believed to drive many of those protective effects. LNS8801 is designed to activate GPER, a receptor involved in resilience across multiple tissues.
A useful way to think about it is this: instead of flooding the system with hormones, the drug aims to gently turn on a switch the body already uses to protect itself. The promise is broad, but the approach is targeted.
What makes LNS8801 particularly unusual in the longevity space is its origin story. It wasn’t developed as an “aging drug.” It emerged from oncology – from cancer trials to aging prevention.
More than 100 cancer patients have already received LNS8801 in early-stage clinical studies. Those trials showed an exceptional safety and tolerability profile, an essential prerequisite for any drug intended for healthy older adults.
But researchers noticed something else. Alongside signals of improved survival, patients also showed improvements in cardiometabolic measures, including LDL cholesterol, blood pressure, HbA1c and body weight. Those markers are closely tied to how well people age.
Dr Patrick Mooney, chief executive officer of Linnaeus, says ARPA-H’s decision reflects confidence in that broader potential. “ARPA-H’s evaluation of our data and subsequent award validates the promise of LNS8801 to potentially prevent diseases of aging,” he says, pointing to the agency’s emphasis on translating early signals into meaningful healthspan outcomes.
The PROSPR-supported program will unfold in phases, beginning with preclinical aging studies and progressing to a randomized clinical trial in healthy older adults. Crucially, success won’t be defined solely by lab values.
Researchers will assess how participants function – how they move, think and maintain independence – alongside physiological markers and emerging measures of biological aging. It’s a more holistic view that reflects how aging is actually experienced.
From ARPA-H’s perspective, that’s exactly the point. “Since cardiometabolic health naturally declines with age, the preliminary data suggesting LNS8801 improves these in humans is compelling,” says Andrew Brack, the agency’s program manager for PROSPR.
A preview of longevity medicine’s future
If the approach works, its implications extend far beyond a single drug. Preventing decline rather than reacting to it could reshape how healthcare systems allocate resources, shifting emphasis toward resilience and away from late-stage intervention.
Linnaeus’ award underscores that aging biology is becoming a legitimate target for preventive medicine, not just a backdrop to disease. Drugs developed for cancer or metabolic disorders are being re-evaluated for what they reveal about how the body maintains balance over time.
READ MORE: ARPA-H pours millions into healthspan-focused human trials
